Quarterly report · Q2
3034.TEDINET S100SA13
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥82.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥101.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥91.0bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥57.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥53.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥45.9bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.58 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.11 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.92 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥231m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥231m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.6bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥167m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥658m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥231m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.9bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥123m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥645m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥82.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥82.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥181m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥5.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 4000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 3000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -39000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -51000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -2904000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -1860000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 4711000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 6391000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | － | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -1000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -1087000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -1239000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 1000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 55000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -144000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -115000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 2000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 4000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -82000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | -72000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | 61000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | 34000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -759000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1YTDDuration | － | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | CurrentYTDDuration | -7500000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1YTDDuration | -426000000 | JPY |
| Payments for transfer of business2 inv cf | CurrentYTDDuration | -253000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -5000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -59000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -1681000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -9905000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 7500000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -4547000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -4493000000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -454000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -338000000 | JPY |
| Proceeds from disposal of treasury stock fin cf | Prior1YTDDuration | 172000000 | JPY |
| Proceeds from disposal of treasury stock fin cf | CurrentYTDDuration | 168000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -527000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -640000000 | JPY |
| Proceeds from sale and leaseback fin cf | Prior1YTDDuration | 138000000 | JPY |
| Proceeds from sale and leaseback fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | -4000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -25000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -5223000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 2170000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -2193000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1343000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |